


Claims

1. A compound represented by the formula (I)



5 wherein X is S or O,

R¹ and R² are the same or different and each is a hydrogen atom, an optionally substituted C₆₋₁₄ aryl group, an optionally substituted heterocyclic group or an optionally substituted C₁₋₆ alkyl group, or R¹ and R² are bonded to each other to form a
 10 ring together with the carbon atom they are bonded to,
 E is -W¹-N(R⁵)-W²-, -W¹-CH(R⁶)-O-W²-, -W¹-O-CH(R⁶)-W²-,
 -W¹-S(O)_n-W²- or -W¹-CH(R⁶)-W²- (W¹ and W² are the same or
 different and each is a bond or an optionally substituted C₁₋₃
 15 alkylene group, R⁵ and R⁶ are each an optionally substituted
 heterocyclic group or an optionally substituted hydrocarbon
 group, and n is 1 or 2, provided that when X is S, then R⁵ and
 R⁶ are not C₁₋₆ alkyl groups),
 ring S¹ is a benzene ring or pyridine ring each optionally
 further having substituent(s) selected from an optionally
 20 substituted C₁₋₆ alkyl group, an optionally substituted C₁₋₆
 alkoxy group and a halogen atom,
 R³ and R⁴ are the same or different and each is a hydrogen
 atom, a halogen atom, an optionally substituted C₁₋₆ alkyl group
 or an optionally substituted C₁₋₆ alkoxy group,
 25 R⁹ and R¹⁰ are the same or different and each is a hydrogen
 atom, a halogen atom or a C₁₋₆ alkoxy group, and
 R is an optionally substituted hydroxy group or an optionally
 substituted amino group,
 or a salt thereof.

30

2. The compound of claim 1, wherein E is -W¹-N(R⁵)-W²-,
 -W¹-CH(R⁶)-O-W²-, -W¹-O-CH(R⁶)-W²- or -W¹-CH(R⁶)-W²- (W¹ and W²

are the same or different and each is a bond or an optionally substituted C₁₋₃ alkylene group, and R⁵ and R⁶ are each an optionally substituted heterocyclic group or an optionally substituted hydrocarbon group, provided that when X is S, then
5 R⁵ and R⁶ are not C₁₋₆ alkyl groups),
ring S¹ is a benzene ring optionally further having substituent(s) selected from an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₁₋₆ alkoxy group and a halogen atom, and
10 R⁹ and R¹⁰ are hydrogen atoms,
or a salt thereof.

3. A prodrug of a compound of claim 1 or a salt thereof.

15 4. The compound of claim 1, wherein R³ and R⁴ are the same or different and each is a hydrogen atom or a halogen atom, or a salt thereof.

5. The compound of claim 1, wherein E is -W¹-N(R⁵)-W²- (W¹ and
20 W² are the same or different and each is a bond or an optionally substituted C₁₋₃ alkylene group, and R⁵ is an optionally substituted heterocyclic group or an optionally substituted hydrocarbon group, provided that when X is S, then R⁵ is not a C₁₋₆ alkyl group), or a salt thereof.

25

6. The compound of claim 5, wherein R⁵ is an optionally substituted C₇₋₁₆ aralkyl group, or a salt thereof.

7. The compound of claim 1, wherein R is a hydroxy group, or a
30 salt thereof.

8. The compound of claim 1, wherein X is S, or a salt thereof.

9. The compound of claim 1, wherein ring S¹ is a benzene ring,
35 or a salt thereof.

10. The compound of claim 1, wherein both R⁹ and R¹⁰ are hydrogen atoms, or a salt thereof.
- 5 11. 3-[4-[[4-[(2-Phenylethyl) (4-phenyl-1,3-thiazol-2-yl)amino]methyl]benzyl]oxy]phenyl]propanoic acid,
3-[2,6-difluoro-4-[[4-[(2-phenylethyl) (4-phenyl-1,3-thiazol-2-yl)amino]methyl]benzyl]oxy]phenyl]propanoic acid,
2-fluoro-3-{4-[(4-[(2-phenylethyl) (4-phenyl-1,3-thiazol-2-yl)amino]methyl)benzyl]oxy]phenyl}propanoic acid,
10 3-{2-fluoro-4-[(4-{1-[(4-phenyl-1,3-thiazol-2-yl)sulfonyl]butyl}benzyl)oxy]phenyl}propanoic acid, or a salt thereof.
- 15 12. A GPR40 receptor function modulator comprising a compound of claim 1 or a salt thereof or a prodrug thereof.
13. A pharmaceutical agent comprising a compound of claim 1 or a salt thereof or a prodrug thereof.
- 20 14. The pharmaceutical agent of claim 13, which is an agent for the prophylaxis or treatment of diabetes.
15. Use of a compound of claim 1 or a salt thereof or a prodrug thereof for the production of a GPR40 receptor function modulator.
- 25 16. Use of a compound of claim 1 or a salt thereof or a prodrug thereof for the production of an agent for the prophylaxis or treatment of diabetes.
- 30 17. A method of modulating GPR40 receptor function in a mammal, which comprises administering an effective amount of a compound of claim 1 or a salt thereof or a prodrug thereof to the mammal.
- 35

18. A method for the prophylaxis or treatment of diabetes in a mammal, which comprises administering an effective amount of a compound of claim 1 or a salt thereof or a prodrug thereof to
5 the mammal.